Zogenix, Inc. (ZGNX) News
Filter ZGNX News Items
ZGNX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ZGNX News Highlights
- ZGNX's 30 day story count now stands at 3.
- Over the past 2 days, the trend for ZGNX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- BEAT, PATH and RARE are the most mentioned tickers in articles about ZGNX.
Latest ZGNX News From Around the Web
Below are the latest news stories about Zogenix Inc that investors may wish to consider to help them evaluate ZGNX as an investment opportunity.
Analysts Estimate Envestnet (ENV) to Report a Decline in Earnings: What to Look Out forZogenix (ZGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Zogenix (ZGNX) May Report Negative Earnings: Know the Trend Ahead of Q4 ReleaseZogenix (ZGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Zogenix Supports New No-Cost Genetic Testing Program with United Mitochondrial Disease Foundation to Improve Diagnosis of Mitochondrial DiseasesSymptoms of mitochondrial diseases, such as Thymidine Kinase 2 deficiency (TK2d), can vary widely and mimic other rare and common diseases, making diagnosis challenging 1,2,3Genetic testing offers a quicker, confirmatory path to diagnosis, enabling more accurate care and participation in available clinical trials 1,2,3An estimated 1 in 5,000 individuals has a genetic mitochondrial disease 4 EMERYVILLE, Calif., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical c |
Why Zogenix Flew Higher Before Leveling Off This WeekZogenix (NASDAQ: ZGNX) stock is having the ride of its life this week -- perhaps for the last time in its history. The biotech announced Wednesday it agreed to be acquired by Belgium-based pharmaceutical company UCB (OTC: UCBJF). The company's share price quickly rocketed higher, but it's basically stayed at the enhanced level. |
Biotech Stock Roundup: ZGNX's Acquisition News, REGN, BLUE's Updates & MoreRegulatory and other pipeline updates from Zogenix (ZGNX) and Regeneron (REGN) are among a few key highlights from the biotech sector during the past week. |
Zogenix (ZGNX) Stock Surges on Acquisition Offer From UCBBelgium-based UCB is set to acquire Zogenix (ZGNX) for a total transaction value of $1.9 billion in cash. The transaction is likely to be completed by second-quarter 2022. |
Zogenix (ZGNX) Stock Jumps 65.7%: Will It Continue to Soar?Zogenix (ZGNX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
Zogenix (ZGNX) Received its Third Buy in a RowAfter Needham and Northland Securities gave Zogenix (NASDAQ: ZGNX) a Buy rating last month, the company received another Buy, this time from Mizuho Securities. Analyst Vamil Divan maintained a Buy rating on Zogenix today and set a price target of $55.00. The company's shares closed last Tuesday at $15.64. According to TipRanks.com, Divan is ranked 0 out of 5 stars with an average return of -3.9% and a 44.9% success rate. Divan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Satsuma Pharmaceuticals, and ACADIA Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Zogenix with a $36. |
UCB to Acquire Zogenix; ZGNX Shares Surge 66%Shares of Zogenix (NASDAQ: ZGNX) surged over 66% during the pre-market trading session on January 19, after UCB (Euronext: UCB) inked a deal to acquire Zogenix for $1.9 billion (€1.7 billion). Zogenix, Inc. is a global biopharmaceutical company engaged in the development and commercialization of therapies for rare diseases. Following the news, shares of the Belgium-based multinational biopharmaceutical company, UCB gained around 3% during the pre-market trading hours. Synergies from the Deal The addition of Zogenix will complement UCB's existing therapeutic offerings and enhance the clinical development of a pipeline of epilepsy and rare disease therapies. |
JMP Securities Sticks to Their Hold Rating for Zogenix (ZGNX)JMP Securities analyst Jason Butler maintained a Hold rating on Zogenix (ZGNX – Research Report) today. The company's shares closed last Wednesday at $26.12. According to TipRanks.com, Butler is a 1-star analyst with an average return of -1.5% and a 40.1% success rate. Butler covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Aquestive Therapeutics, and ACADIA Pharmaceuticals. Zogenix has an analyst consensus of Moderate Buy, with a price target consensus of $30.00, which is a 15.0% upside from current levels. In a report released today, Needham also downgraded the stock to Hold. |